Synergies between FAM46C expression levels and effectiveness of anti-cancer drug treatment have also been assessed outside of MM, namely in prostate cancer, HCC and CRC, focusing on two drugs: docetaxel and norcantharidin (NCTD). This evidence concerns the gene TENT5C and prostate carcinoma.